Pluvicto, a prostate cancer drug manufactured by Novartis, approved by the FDA in March 2022, has been in short supply for several months due to issues with delivery and manufacturing — but the shortage may be ending, according to NBC News.
Read the full post on Becker's Hospital Review - Healthcare News
